Canada recalls popular anti-aging cream for failing safety tests
Watier cosmetics
, have been recalled due to microbial contamination. The cream is sold at Shoppers Drug Mart and on Amazon.
Tired of too many ads? go ad free now
"This recall involves WATIER Age Control Supreme Sublime Advanced Rich day cream sold in a cylindrical printed glass jar containing 50 mL of cream, in cardboard secondary packaging. The UPC associated with the product and the batch affected by this recall can be found printed on the bottom of the secondary packaging: 058655630646 and (L)23L1757," Health Canada said in an official release.
What are the health risks involved in this?
"The recalled product does not meet microbial standards over time.
The product may contain a microorganism called Lactobacillus pentosus. Lactobacillus pentosus (a probiotic) poses little medical risk to people," the government report says.
Lactobacillus pentosus is a beneficial, lactic acid-producing bacterium commonly found in fermented foods like olives, pickles, and sauerkraut. It's known for its ability to survive in acidic environments and promote gut health by balancing intestinal flora and inhibiting harmful bacteria.
L. pentosus also plays a role in boosting the immune system and may help reduce inflammation in the gut. Some studies suggest it supports digestion and enhances nutrient absorption. Due to its resilience and probiotic properties, it's increasingly being used in functional foods and supplements. Its natural fermentation skills make it a valuable player in both food science and gut wellness.
As of April 22, 2025, the company has received no reports of incidents or injuries in Canada, the Health Canada has said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
11 hours ago
- Economic Times
Health Canada recalls baby nests sold under 'eleven' brand over strangulation and entrapment risks
Synopsis Health Canada has recalled 3,007 BChic and Chicure model baby nests sold under the 'eleven' brand due to fall, strangulation, and entrapment hazards. Sold between February 2020 and July 2025, these soft, fabric-lined nests pose a risk to infants. Consumers are urged to stop using them immediately and dispose of them safely. TIL Creatives Baby nests recalled in Canada amid serious hazards including strangulation and falls Health Canada has issued an urgent recall for two popular infant sleep products after determining they pose serious safety risks, including fall, strangulation, and entrapment hazards. The recall applies to the BChic and Chicure model baby nests sold under the 'eleven' brand by Montreal-based company CHIC BABY. In total, 3,007 units were sold in Canada between February 2020 and July products, soft, fabric-lined cushioned nests, were sold in multiple prints and included a head pillow. The Chicure model, notably, folds into a portable handbag with a carrying handle. All recalled units are marked with a tag labeled 'eleven.'While no injuries or incidents have been reported as of July 18, 2025, Health Canada is urging consumers to stop using the nests immediately and to dispose of them in a way that prevents have long warned against the use of soft-sided sleep accessories for infants. The American Academy of Pediatrics and Health Canada both emphasize that babies should sleep alone, on their back, on a firm and flat surface with no soft bedding or padding. Health Canada urges consumers to: Stop using the recalled products immediately Dispose of them safely so they cannot be reused or resold Contact CHIC BABY via email at info@ for further assistance Consumers are also encouraged to report any related incidents through the Consumer Product Incident Report Form on Health Canada's website. For additional information and updates, parents and caregivers can review Health Canada's official safe sleep guidelines.
Economic Times
25-07-2025
- Economic Times
How long will Canada's pain medicine shortage last, and what can you do?
Synopsis Canada is grappling with a nationwide shortage of prescription pain medications containing acetaminophen with codeine or oxycodone, impacting drugs like Percocet and Tylenol No. 3. Manufacturing disruptions and increased demand are the primary causes. Pharmacists are dispensing limited quantities, and the shortage is expected to last until early August 2025, with a significant resupply anticipated. AP Canada faces a national shortage of key pain medications like Percocet and Tylenol 3, affecting patients across the country. Health Canada cites supply disruptions and rising demand, with relief expected by early August 2025. Canada is currently experiencing a nationwide shortage of some commonly used prescription pain medications. Health Canada issued a notice on July 18 confirming that drugs containing acetaminophen with codeine or oxycodone are in limited supply. These medications are often used to manage moderate to severe affected include combinations of acetaminophen with oxycodone (sold under brand names like Percocet) and acetaminophen with codeine (such as Tylenol No. 3). Other impacted formulations include Teva-Oxycocet, Teva-Lenoltec No. 1 to 4, and Rivacocet. Pharmaceutical companies such as Teva Canada Ltd., Laboratoire Riva Inc., and Pharmascience Inc. have cited manufacturing disruptions and increased demand as reasons for the shortage. To manage the shortage, pharmacists across the country have been dispensing limited quantities. Sadaf Faisal, senior director of professional affairs at the Canadian Pharmacists Association (CPA), told Global News that pharmacists currently supply only a 30-day supply in some cases due to low availability. Some pharmacists are also reaching out to other pharmacies to source additional stock. The CPA expects the shortage to last until early August, with a significant resupply anticipated at that time. In the meantime, Health Canada urges patients to speak with their doctors or pharmacists if they are affected. Alternative pain relief options may be available, but any change in medication requires physician approval due to federal drug are advised to use only licensed pharmacies and avoid unverified online sellers. Health Canada warns that unregulated sources may sell products lacking active ingredients or containing dangerous substances. Canada is facing a shortage of prescription drugs containing acetaminophen with codeine or oxycodone, including Percocet, Tylenol No. 3, Teva-Oxycocet, and Rivacocet. These are commonly used for pain to the Canadian Pharmacists Association (CPA), the shortage is expected to continue until early August 2025, when a significant resupply is should consult their doctor or pharmacist for safe and effective alternatives. Due to Canadian regulations, pharmacists need physician approval before changing or substituting any controlled medications.
Time of India
25-07-2025
- Time of India
Canada faces pain medicine shortage and here's what can you do
Canada is grappling with a nationwide shortage of prescription pain medications containing acetaminophen with codeine or oxycodone, impacting drugs like Percocet and Tylenol No. 3. Manufacturing disruptions and increased demand are the primary causes. Pharmacists are dispensing limited quantities, and the shortage is expected to last until early August 2025, with a significant resupply anticipated. Canada faces a national shortage of key pain medications like Percocet and Tylenol 3, affecting patients across the country. Health Canada cites supply disruptions and rising demand, with relief expected by early August 2025. Tired of too many ads? Remove Ads Pharmacists say limited supply Tired of too many ads? Remove Ads When will supply resume? Health Canada warning FAQs What pain medications are currently in short supply in Canada? How long will the prescription drug shortage in Canada last? Tired of too many ads? Remove Ads What should I do if my prescribed pain medication is unavailable? Canada is currently experiencing a nationwide shortage of some commonly used prescription pain medications . Health Canada issued a notice on July 18 confirming that drugs containing acetaminophen with codeine or oxycodone are in limited supply. These medications are often used to manage moderate to severe affected include combinations of acetaminophen with oxycodone (sold under brand names like Percocet) and acetaminophen with codeine (such as Tylenol No. 3). Other impacted formulations include Teva-Oxycocet, Teva-Lenoltec No. 1 to 4, and companies such as Teva Canada Ltd. , Laboratoire Riva Inc. , and Pharmascience Inc. have cited manufacturing disruptions and increased demand as reasons for the manage the shortage, pharmacists across the country have been dispensing limited quantities. Sadaf Faisal, senior director of professional affairs at the Canadian Pharmacists Association (CPA), told Global News that pharmacists currently supply only a 30-day supply in some cases due to low pharmacists are also reaching out to other pharmacies to source additional CPA expects the shortage to last until early August, with a significant resupply anticipated at that time. In the meantime, Health Canada urges patients to speak with their doctors or pharmacists if they are pain relief options may be available, but any change in medication requires physician approval due to federal drug are advised to use only licensed pharmacies and avoid unverified online Canada warns that unregulated sources may sell products lacking active ingredients or containing dangerous is facing a shortage of prescription drugs containing acetaminophen with codeine or oxycodone, including Percocet, Tylenol No. 3, Teva-Oxycocet, and Rivacocet. These are commonly used for pain to the Canadian Pharmacists Association (CPA), the shortage is expected to continue until early August 2025, when a significant resupply is should consult their doctor or pharmacist for safe and effective alternatives. Due to Canadian regulations, pharmacists need physician approval before changing or substituting any controlled medications.
